Some concerns raised by the FDA about a fuzzy trial design used by Novo Nordisk AS for a fixed-dose formulation that unites two of its already marketed drugs – Victoza (liraglutide), a glucagon-like peptide 1 (GLP-1) receptor agonist, and Tresiba (insulin degludec), a basal insulin – may throw a wrench into the firm's hope of turning the combo product into what the Danish company is hoping will be a big moneymaker.
The FDA wants its Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) to help the agency grapple with various issues with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?